Edgewise Therapeutics, Inc.
EWTX
Rangering i aksjer
#4009
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Aksjekurs
$37.82
Markedsverdi
$4.07B
Endring (1 dag)
1.69%
Endring (1 år)
151.13%
Land
US
Handel Edgewise Therapeutics, Inc. (EWTX)
Kategori
Healthcare
Utbyttehistorikk for Edgewise Therapeutics, Inc. (EWTX)
Edgewise Therapeutics, Inc. (aksjesymbol: EWTX) har gitt totalt 0 utbyttebetalinger.
Summen av alle utbytter (justert for aksjesplitt): 0.00
Utbytteavkastning (TTM): 0
Summen av alle utbytter (justert for aksjesplitt): 0.00
Utbytteavkastning (TTM): 0
Utbyttebetalinger for Edgewise Therapeutics, Inc. (EWTX) fra 2026 til 2026
Årlige utbyttebetalinger
| År | Utbytte (justert for aksjesplitt) | Endre |
|---|---|---|
| Ikke nok data for de angitte datoene. | ||
Liste over alle utbyttebetalinger
| År | Utbytte | Endre |
|---|---|---|
| Ikke nok data for de angitte datoene. | ||
Utbyttebetalinger for lignende selskaper eller konkurrenter
| Selskap | Antall utbyttebetalinger | Land |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
